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Increased cyclooxygenase-
2, hyperfiltration, 
glomerulosclerosis, and diabetic 
nephropathy: put the blame on 
the (pro)renin receptor?
G Nguyen1
Interaction between the renin–angiotensin system and 
cyclooxygenases in the kidney regulates renal microcirculation.  
Activation of the (pro)renin receptor has profibrotic effects, and now 
Kaneshiro et al. show that it also increases COX-2 synthesis. These 
results  may have therapeutic implications, as blocking (pro)renin–
receptor interaction would prevent the increase of angiotensin 
generation and prostaglandin synthesis, two phenomena underlying 
the pathogenesis of diabetic nephropathy.
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Diabetes mellitus is a fascinating patho-
logical situation associated with high 
prorenin and low renin concentrations 
in plasma, resulting in low plasma renin 
activity and a tissue activation of the 
renin–angiotensin system especially in 
the kidney. Renin exists in two forms, 
mature active renin and the inactive 
proenzyme prorenin (hereafter the 
term (pro)renin will refer to prorenin 
and renin collectively). Although many 
tissues can synthesize and secrete 
prorenin, the cleavage of 43 amino acids 
of the prosegment of prorenin, yielding 
mature renin, takes place only in the 
juxtaglomerular apparatus, precisely in 
the myo-epithelioid cells of the aff erent 
glomerular artery, and there is no known 
physiological processing of prorenin into 
renin in plasma or tissue (reviewed by 
Danser1). How can we reconcile the 
fact that the occurrence of microvas-
cular complications in diabetes, such 
as microalbuminuria, is correlated with 
inactive prorenin and not active renin 
levels, and the paradoxical activation of 
the renal renin–angiotensin system and 
increased angiotensin II (Ang II) genera-
tion? Because renin controls the rate-lim-
iting step of angiotensinogen cleavage in 
angiotensin I, one would expect a lower 
degree of activation of the renin–angi-
otensin system and not the contrary.
Th e (pro)renin receptor may provide 
one explanation. Th e receptor binds spe-
cifi cally renin and prorenin and, upon 
binding renin, increases its catalytic 
activity, and prorenin displays full enzy-
matic activity similar to that of mature 
renin;2 thus the receptor can be regarded 
as a means to amplify angiotensin gen-
eration at the cell surface. In addition, 
binding of renin and prorenin triggers 
extracellular signal-regulated kinase-
1/2 activation that may have profi brotic 
consequences.3 Ichihara et al. hypoth-
esized that inhibition of prorenin bind-
ing to the receptor would have benefi cial 
eff ects in diabetes. As no antagonist to 
the (pro)renin receptor is available, they 
tested a peptide against the prorenin 
‘handle region,’ a region described by 
Suzuki et al. to be involved in prorenin 
conformational change and non-proteo-
lytic activation.4 Indeed, these authors 
showed that infusion of the ‘handle 
region’ decoy peptide (HRP) was able 
to reduce local Ang II generation and 
fi brosis in an impressive set of experi-
mental rat models including streptozo-
tocin-induced diabetes,5 cardiac fi brosis 
in stroke-prone spontaneously hyper-
tensive (SHR) rats,6 and ocular infl am-
mation in endotoxin-induced uveitis.7 
Furthermore, these authors also reported 
the prevention of glomerulosclerosis by 
HRP infusion in streptozotocin dia-
betic Ang II receptor type 1a–/– mice, 
indicating that the profibrotic effect 
of prorenin–receptor interaction was 
essentially mediated by phosphorylation 
of the mitogen-activated protein kinases 
due to (pro)renin receptor activation 
and not to Ang II generation.8 These 
results raise two questions: (1) Renin 
also binds to the receptor with affin-
ity even higher than that of prorenin,2 
indicating that (pro)renin binding is not 
dependent on the prosegment that was 
cleaved during the maturation process, 
and HRP inhibits only prorenin bind-
ing. Th erefore, why should inhibition of 
prorenin binding be suffi  cient to prevent 
all receptor activation and pathogenic 
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effects when renin also is increased, 
such as in SHR, or probably normal, 
such as in receptor-transgenic rats and 
in uveitis? Experimental data have dem-
onstrated the uptake of renin in diff erent 
organs, therefore ruling out the possi-
bility of selective uptake of prorenin by 
tissues, and it is diffi  cult to imagine that 
mature renin has no role at all in vivo 
in the tissue renin–angiotensin system. 
(2) Prorenin represents the majority 
of total renin in normal subjects, and 
prorenin levels are increased in pregnant 
women. What is the diff erence in recep-
tor activation in these two physiologi-
cal situations and diabetes, and how is 
receptor activation controlled in physio-
logical states as compared with diabetes? 
So far, there is no evidence that renin 
and prorenin may activate the receptor 
diff erently and should be considered as 
the two distinct faces of Janus.
To study further the mechanisms 
underlying the pathogenic effects of 
(pro)renin receptor activation in diabetic 
nephropathy, Kaneshiro et al.9 focused 
on the relation between the (pro)renin 
receptor and cyclooxygenase-2 (COX-2). 
Th ere is a tight relation between renin, 
Ang II, and prostaglandins in the kidney 
and COX-2 expression is increased in 
disease models and in the human and the 
rat diabetic kidney. In the diabetic kidney, 
COX-2 may be responsible for the hyper-
fi ltration state due to the dilatation of the 
aff erent glomerular arteriole. Th e induc-
ible form of cyclooxygenase, COX-2, can 
be detected in macula densa cells, albeit 
at low levels, in basal states, and, para-
doxically, COX-2 increases renin release 
via the synthesis of prostaglandin I2. Th e 
factors involved in COX-2 upregulation 
in diabetes are unknown, and Kaneshiro 
et al.9 hypothesized that one benefi cial 
eff ect of HRP in diabetic nephropathy 
might be due to the inhibition of COX-
2 increase. To test this hypothesis, they 
used a rat model with ubiquitous over-
expression of the human receptor. Th is 
model would have the advantage that 
rat prorenin can bind and activate the 
human receptor but is not activated by a 
conformational change and cannot cleave 
angiotensinogen. Th erefore, the eff ect on 
COX-2 regulation would be attributed 
only to (pro)renin receptor activation 
and intracellular signaling and not to 
Ang II generation. And indeed, trans-
genic rats overexpressing the receptor 
mostly in tubular cells, including cells of 
the macula densa, have increased expres-
sion of COX-2 and normal renal Ang II 
content, precluding the role of Ang II in 
COX-2 upregulation. In addition, these 
authors report increased extracellular 
signal-regulated kinase-1/2 activation 
in the cortex of transgenic rats.9 Th ese 
results suggest that a moderate overex-
pression of (pro)renin receptor in mac-
ula densa cells increases the expression of 
COX-2 by activating the extracellular sig-
nal-regulated kinase-1/2 pathway. How-
ever, it is interesting to note that, in rats 
as in humans, the main site of synthe-
sis of (pro)renin receptor in the normal 
kidney is the distal tubule, as shown by 
immunohistochemistry and confi rmed 
by in situ hybridization (Figures 1 and 
2). Th ere is a strong labeling of the recep-
tor at the basolateral side of distal tubular 
cells and in characteristic macula densa 
cells (Figure 1b) that was not visible by 
immunofl uorescence,2 suggesting that 
part of the receptor is tightly associated 
with other cellular proteins and that it 
needs to be denatured to fully expose all 
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Figure 1 | Immunolocalization of (pro)renin receptor in human kidney. Normal human kidney 
was stained with a polyclonal anti-human receptor antibody. (a) In the cortex, the staining is visible 
in distal tubules and in glomeruli. (b) At higher magnification, we can note the staining in the 
glomerulus and in the cells of the macula densa (arrow). (c) In the juxtaglomerular apparatus, the 
afferent and efferent arterioles are negative. (d) A higher magnification of the distal tubules shows 
the basolateral localization of the receptor.
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Figure 2 | Comparison of (pro)renin receptor expression in human (a) and in rat kidney (b) by 
immunohistochemistry and by in situ hybridization in human kidney (c and d) with radioactive 
probe. Panels (c) and (d) are the same photograph in dark field and in bright field, respectively.
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The clot thickens
AB Fogo1
Vascular sclerosis has been linked to many risk factors, including 
smoking, family history, low birth weight, and hypertension. In 
interesting studies, Goforth et al. show an increased rate of mutations 
in thrombophilic molecules in patients with vascular sclerosis in renal 
biopsies, suggesting yet another mechanism.
Kidney International (2006) 70, 620–621. doi:10.1038/sj.ki.5001721
epitopes. Th at a moderate overexpression 
of the receptor in macula densa cells is 
responsible for a signifi cant increase of 
COX-2 expression again suggests an 
extremely tight control of the eff ects of 
receptor activation in basal states.
Th ere is an increasing interest in the 
(pro)renin receptor, probably because 
it provides now a functional role for 
prorenin that was suspected long ago. 
The mechanism of control of recep-
tor expression and desensitization is 
unknown so far. Th e elucidation of the 
molecular basis of the control of recep-
tor activation in normal tissue, the study 
of the degree of receptor expression 
in pathological states, and the conse-
quences of receptor overactivation now 
merit attention, and these studies would 
undoubtedly improve our knowledge of 
the tissue renin–angiotensin system.
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Th e etiology and pathogenesis of vas-
cular sclerosis have remained obscure, 
despite multiple levels of investigation. 
Th ese studies have examined a variety of 
possible factors, including smoking, obe-
sity, family history, and even low birth 
weight. A major focus has been on the 
well-known link between hypertension 
and accelerated vascular disease. How-
ever, vascular sclerotic lesions did not 
correlate with extent of hypertension in a 
biopsy study of presumed arterionephro-
sclerosis in African Americans.1 Further, 
the extent of sclerosis of arterioles and 
arteries did not correlate with the extent 
of global glomerulosclerosis. In a retro-
spective study examining biopsies done 
for clinical indications, vascular sclerosis 
and glomerulosclerosis were more severe 
in African Americans than in whites.2 
However, in neither population was 
mean arterial pressure predictive of these 
morphologic lesions. In a large review of 
renal biopsies, Meyrier et al. found that 
degree of vascular sclerosis did not corre-
late with hypertension, and surprisingly, 
vascular sclerosis was even present at 
moderately severe levels in tubulointer-
stitial disease processes.3 Further, not all 
patients who exhibit hypertension show 
signifi cant vascular lesions, particularly 
in the white population.4
These findings have pointed to the 
possibility of unrecognized factors 
other than blood pressure accounting 
for sclerosis of the vasculature. In the 
interesting study by Goforth et al.5 (this 
issue), the possibility of contribution of 
inherited thrombophilia to vascular 
sclerosis was investigated. Th ey studied 
renal biopsies in adult patients with vas-
cular sclerotic lesions, defi ned morpho-
logically by intimal fi brosis and medial 
hypertrophy, excluding cases of immune 
complex glomerulonephritis. Patients 
were then further categorized as those 
with diabetes, hypertension, or both, 
those who smoked, and, fi nally, those 
with vascular sclerosis of unknown eti-
ology. Genomic DNA extracted from 
remaining frozen tissue from these 
biopsies was then investigated to iden-
tify any mutations in the gene for factor 
V or for prothrombin, or mutation in a 
gene that causes hyperhomocysteinemia 
(methylenetetrahydrofolate reductase, 
MTHFR). Interestingly, among patients 
without known risk factors for vascular 
disease, such as diabetes, hypertension, 
or smoking, a signifi cant proportion had 
mutations in one or more of these three 
genes. Th e small sample size precludes 
broad conclusions regarding other 
populations. However, the clustering of 
mutations in about half of the previously 
considered idiopathic vascular sclerosis 
group is of great interest.
Th e contribution of factors govern-
ing hemostasis to acute thrombotic 
lesions and also vascular sclerosis has 
previously been recognized. Th us, plas-
minogen activator inhibitor-1 (PAI-1) 
is associated with increased risk for 
cardiovascular and renal disease.6,7 
PAI-1 levels are also regulated at the 
genetic level, with polymorphic variance 
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